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Abstract
Gene expression and inheritance are not only a function of the DNA code, but also
epigenetic mechanisms that regulate DNA accessibility, transcription, and translation
of the genetic code into a functional protein. Epigenetic mechanisms are invoked by life
experiences, including stress and exposure to drugs of abuse, and the resulting changes
in gene expression can be inherited by future generations. This chapter highlights recent
research demonstrating epigenetic changes in response to drug exposure with a focus
on three different mechanisms: DNA methylation, histone modification, and noncod‐
ing RNAs. We briefly describe each of these mechanisms and then provide key examples
of drug-induced changes involving these mechanisms, as well as epigenetic manipula‐
tions that alter effects of drugs. We then review cutting-edge technologies, including
viral-mediated gene  transfer  and gene  editing,  that  are  being  used to  manipulate
epigenetic  processes with temporal  and cell-type specificity.  We also describe and
provide  examples  of  intergenerational  epigenetic  modifications,  a  topic  that  has
interesting implications for how addiction-related traits may be passed down across
generations. Finally, we discuss how this research provides a greater understanding of
drug addiction and may lead to novel molecular targets for preventions and interven‐
tions for drug abuse.
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1. Introduction
One of the most compelling questions in the field of drug abuse is why some individuals who
experiment with drugs go on to develop substance use disorders (SUDs) while others do not.
Both a family history of SUDs and stressful life events increase one’s vulnerability to develop
SUDs [1, 2]. Historically, these risk factors were viewed as “nature and nurture” making separate
contributions to an addiction phenotype. However, recent advances in the field of epigenetics
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demonstrate that “nurture” changes “nature” by modifying whether or not a given gene will
be expressed. Understanding how one’s environment (e.g., drug-taking behavior, stress, and
learning) can alter gene expression in the brain may give insight into how drug addiction
develops, how it may be passed down into future generations, and perhaps, how it can be better
treated.
While the DNA sequence of a gene can be modified directly (e.g., mutations, deletions,
insertions, translocations, etc.) resulting in altered gene expression, epigenetics regulates gene
expression by mechanisms other than changes to the DNA sequence. It has long been known
that epigenetic mechanisms largely control cell differentiation by allowing some genes to be
expressed and others to be silenced at various points in time during development. Indeed,
even though all human cells possess the same DNA (with the exception of egg and sperm cells),
what differentiates a given cell type from others (e.g., a neuron versus a liver cell) is the
epigenetic mechanisms that permit or deny its genes to be transcribed and translated into cell
type-specific functional proteins [3]. Beyond the hard-wire epigenetic programming of gene
expression during development, epigenetic mechanisms also provide dynamic and heritable
means of altering gene expression in response to environmental change. For example, either
stressful life experiences or a history of chronic drug intake can invoke chemical modifications
to either the DNA or the histone proteins that are involved in storing the DNA. Such epigenetic
changes have an impact on how accessible the DNA is for gene transcription. Epigenetic
changes can also be long lasting and passed down to future generations. In this way, not only
does experience with stress and/or drugs place one’s self at risk for SUDs, but also one’s
offspring due to heritable epigenetic modifications. Even in the more proximal time frame of
an individual’s lifespan, epigenetic mechanisms provide a “working memory” for gene
expression changes that are involved in brain plasticity [4]. Brain plasticity changes resulting
from drug exposure are thought to be the crux of the dysfunction underlying addiction [5]. An
exciting implication of understanding the role of epigenetic changes in drug-induced brain
plasticity is that new strategies for therapeutic interventions may be discovered.
In this chapter, we review three epigenetic mechanisms that have been found to impact drug
abuse-related behaviors in animal models: (1) chemical modifications to DNA, (2) chemical
modifications to histones, and (3) the induction of noncoding RNAs that regulate gene
expression. We will begin with a brief explanation of how drugs modify intracellular signaling
pathways that propagate to the cell nucleus, leading to epigenetic changes. We will then
provide a brief description of the epigenetic mechanisms listed above, followed by examples
of how drugs of abuse invoke these mechanisms and how pharmacologically targeting the
epigenome can alter drug-abuse-related behavior. Next, we will cover the latest developments
in genetic tools that provide precise manipulation of epigenetic enzymes, further elucidating
the roles of these specific molecules. We will also review literature supporting transgenera‐
tional inheritance of epigenetic changes associated with a history of drug intake. We conclude
by discussing important future directions for research investigating epigenetic mechanisms
associated with drug addiction.
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2. The link between drug action, intracellular signaling, and epigenetic
changes
Both endogenous neurotransmitters and drugs interact with neuronal proteins, such as
neurotransmitter receptors, proteins involved in synaptic homeostasis (e.g., neurotransmitter
metabolic enzymes, transporters, etc.), and proteins involved in intracellular signaling
pathways. These intracellular signaling pathways can propagate to the cell nucleus, leading
to changes in gene expression [6]. Often, the first change observed in the cell nucleus following
an environmental perturbation (e.g., drug use, stress, novelty, etc.) is the expression of
immediate early genes (IEGs). Common IEGs encode transcription factors that increase
expression of other target genes by binding to the genes’ promoter region, which is a sequence
in the DNA that signals the cell to initiate transcription [7, 8]. IEGs are rapidly induced and
are often used as a marker of changes in neuronal signaling activity [9]. Both IEGs and target
genes may undergo epigenetic modifications that regulate their expression. Thus, either
natural signaling in response to environmental stimuli or drug-induced changes in signaling
can invoke epigenetic mechanisms that alter gene expression. The dynamics of the epigenetic
changes may be specific to the degree and phase of drug exposure, where particular epigenetic
marks may only arise (or disappear) following acute or chronic drug administration, or during
a period of withdrawal from drug use [10].
3. DNA epigenetic modification
A given gene is composed of a sequence of nucleotide base pairs in the DNA that are unique
to that gene. For coding genes, the DNA sequence of base pairs serves as the blueprint for
making a particular protein. Given that proteins are the machinery for cell structure and
function, gene expression changes in a neuron can alter cell protein composition and, in turn,
change the way that the neuron functions and communicates with other neurons.
There are four different nucleotide bases that compose the sequence portion of the DNA
molecule, including the pyrimidines cytosine (C) and thymine (T), and the purines adenine
(A) and guanine (G). Due to the structures of these nucleotides, the chemical bond responsible
for base pairing can only form between C and G or A and T, respectively. Cs followed by Gs
in the DNA sequence (i.e., CpGs) can be modified by a reaction in which DNA methyltrans‐
ferases (DNMTs) add a methyl group (CH3) to the 5-position of the C to form 5mC. Intracellular
signals may initiate newly synthesized de novo DNA methylation, which is mediated by DNMT
subtypes DNMT3a and DNMT3b. Subtype DNMT1, on the other hand, maintains DNA
methylation patterns across cell replication, such that the newly synthesized DNA has the exact
methylation pattern that existed before DNA replication. In general, DNA methylation is
correlated with a decrease in DNA accessibility and therefore is thought to be a mechanism of
silencing gene expression. Methylated DNA can silence gene expression by interfering with
the binding of transcriptional activators or by binding to proteins with a methyl-CpG-binding
domain (MBD), such as methyl-CpG binding protein 2 (MECP2), that then form a complex
with other proteins that together repress DNA accessibility [11].
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Historically, DNA methylation was believed to be a permanent modification. However,
demethylation of DNA can occur and also contributes to dynamic changes in gene expression.
While passive demethylation in dividing cells may be due to malfunctioning of DNMT1, active
demethylation occurs in both dividing and nondividing cells by enzymatic reactions. One
reaction changes 5mC into a T, which is then recognized as a G/T mismatch. The mismatch
activates a base excision repair (BER) pathway that utilizes thymine DNA glycosylase (TDG)
and ultimately replaces T with a nonmethylated C [12]. Another reaction catalyzed by 10–11
translocation enzymes (TET) adds a hydroxyl (–OH) group to 5mC forming 5hmC. 5hmC itself
has effects on gene expression and it can undergo further reactions that convert it back to a
nonmethylated C [13]. Therefore, demethylation of DNA is generally correlated with an
increase in DNA accessibility.
4. DNA methylation changes associated with drugs of abuse
Although DNA methylation is typically a stable epigenetic process, drugs of abuse have been
shown to alter both DNA methylation and its associated enzymes. Much of this research has
focused on DNA methylation in the nucleus accumbens (NAc), a brain region involved in
reward and motivation learning [14]. A well-established marker of repeated exposure to drugs
of abuse is an increase in the transcription factor ∆FosB protein in the NAc [15]. Acute or
repeated cocaine administration decreases methylation at the fosB promoter in the NAc of
rodents, which co-occurs with increases in fosB mRNA expression [16]. This may serve as a
mechanism by which exposure to drugs of abuse produces stable increases in ∆FosB protein
expression. Acute or chronic cocaine administration also increases Dnmt3a mRNA and MeCP2
protein expression in the NAc [16–18]. These increases are accompanied by decreases in
psychostimulant reward as measured by conditioned place preference (CPP), a procedure in
which an animal experiences a drug state while confined to one compartment of an apparatus
and a neutral state while confined to an alternate compartment during conditioning, resulting
in a shift in the animal’s preference for the drug-paired compartment when given free access
to both compartments. The decreased CPP effects are believed to be mediated by Dnmt3a- and
MeCP2-induced silencing of genes that encode proteins that are needed for adaptation and
functioning of NAc neurons [17, 18]. In addition, the TET enzyme that catalyzes DNA
demethylation and subsequent transcriptional activation via conversion of 5mC to 5hmC [19]
is decreased in the NAc in both rodents following cocaine administration and in postmortem
tissue from human cocaine addicts [20]. Paradoxically, this decrease in TET is associated with
increases in 5hmC expression at specific gene loci that have previously been linked to addiction
[20]. Further investigation is needed to explain this complex pattern of epigenetic changes.
5. Histone modification
In order for the long strands of DNA to fit within a cell’s nucleus, DNA is tightly condensed
into chromatin. Chromatin is made up of nucleosomes that contain a histone protein core
comprised of two copies of each of four different histone proteins, H2A, H2B, H3, and H4, as
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well as 147 base pairs of DNA that is wrapped around the histone core (Figure 1). Chromatin
can either be tightly (i.e., heterochromatin) or loosely packaged (i.e., euchromatin), where the
former restricts and the latter permits gene expression. Chromatin is able to undergo dynamic
remodeling by chemical modification of amino acid residues of the histone core proteins.
Similar to DNA methylation, histone proteins can undergo post-translational addition or
removal of one of several chemical groups via enzymatic reactions. There are more than 100
different posttranslational modifications that may occur and these changes correlate with
either the activation or the suppression of gene expression.
Figure 1. DNA and histone chemical modifications. DNA (blue lines) wraps around pairs of histone proteins H2A,
H2B, 3, and 4 (light pink and tan) that form an octomer histone protein core. (A) Closed chromatin, due to DNA meth‐
ylation (Me; red) and histone dimethylation on H3K9 (Me; orange), leads to transcriptional repression. (B) Open chro‐
matin, due to DNA hydroxymethylation (hMe; yellow) and histone acetylation (Ac; green), allows for transcription
factors (TF; purple) to recruit RNA polymerase for transcription initiation.
A powerful technique for studying post-translational histone modifications is chromatin
immunoprecipitation (ChIP). ChIP utilizes antibodies that bind specifically to chemically
modified histone proteins, which can then be isolated along with the associated DNA (i.e.,
promoter regions, gene bodies, etc.) from the rest of the tissue. Next, histones and DNA
segments are denatured and levels of specific DNA sequences are measured. This technique
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can be used to (1) determine which gene or gene promoter may be associated with a specific
histone modification, (2) correlate changes in histone modification with expression of specific
genes, and (3) suggest possible mechanisms for how a gene is turned on or off following an
experimental manipulation (e.g., drug administration).
6. Histone modifications associated with drugs of abuse
6.1. Acetylation
Acetyl groups are added to histone proteins, typically on a lysine residue, by histone acetyl
transferases (HATs). Addition of acetyl groups leads to a more relaxed, less condensed
chromatin state by negating the positive charge of the histone protein that is attracted to the
negatively charged DNA (Figure 1B). Indeed, increases in drug-induced gene expression often
positively correlate with the levels of histone acetylation.
Previous work has found widespread changes in acetylation of histone H3 and H4 subunits
in the NAc following acute and repeated psychostimulant administration in rodents [21, 22],
suggesting that many genes in the NAc may be primed for transcription, while others are
suppressed. Acute cocaine administration induces expression of the IEGs c-fos and fosB in
rodents [16, 23], and ChIP analysis revealed increases in H4 acetylation at the respective
promoter regions of these genes [21]. With repeated cocaine administration, the increase in
fosB expression is maintained and is associated with increases in H3 acetylation at the fosB
promoter region [21]. This mechanism likely contributes to ∆FosB protein accumulation in the
NAc following repeated drug exposure. Repeated cocaine administration also reduces the
ability of cocaine to induce c-fos and this is accompanied by a reduction in H4 acetylation at
the c-fos promoter region [21, 24]. Furthermore, chronic opiate administration decreases
expression of another IEG, brain-derived neurotrophic factor (Bdnf), and decreases H3
acetylation at the Bdnf promoter in the ventral tegmental area (VTA) [25]. Bdnf is critical for
the development and maintenance of synaptic structure and function [26, 27] and drugs of
abuse exert their reinforcing effect primarily by activating mesocorticolimbic dopamine
neurons that originate in the VTA and project to the NAc, prefrontal cortex (PFC), amygdala,
and hippocampus [28, 29].
Additionally, alcohol withdrawal in rodents reduces expression of the IEGs activity-regulated
cytoskeleton protein (Arc) and Bdnf in the amygdala along with decreases in H3 acetylation at
the respective gene promoters [30]. The amygdala is involved in processing emotional
memories and it plays a critical role in alcohol-related behavior and anxiety [31]. Although
these examples suggest functional links between degree of acetylation and associated gene
expression, histone acetylation may occur even without changes in gene expression [32].
Therefore, further work into the causal role of acetylation in drug-induced gene expression is
required.
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6.2. Methylation
In contrast to histone acetylation, methylation can be associated with both transcriptional
activation and repression, depending on which histone residue is modified. For example,
dimethylation of histone H3 Lysine 9 (i.e., H3K9me2) is commonly associated with transcrip‐
tional repression. One histone methyltransferase that catalyzes H3K9me2, G9a, is decreased
in the NAc following both chronic cocaine and opiate administration [33, 34]. It should be
noted that this also occurs following chronic social stress in mice that produces depressive-
like behavioral phenotypes, including decreased social interaction and increased anhedonia
[35]. Similarly, G9a is decreased in postmortem NAc tissue of clinically depressed patients [35].
Decreases in G9a are associated with increases in cocaine and morphine CPP [33, 34]. Inter‐
estingly, G9a opposes expression of ∆FosB [33, 34]. In turn, ∆FosB represses G9a expression,
creating a feedback loop that perpetuates its own expression through disinhibition. Similarly,
postmortem NAc brain tissue of human cocaine addicts exhibits decreases in G9a expression
[36] and increases in ∆FosB expression [37], providing further support for a functional link
between these two molecules. In addition to specific genes, compelling work using ChIP and
high-throughput sequencing of the associated genome has shown that cocaine-induced
downregulation of H3K9me2 expression preferentially occurs in nongenic regions of chromo‐
somes [38], suggesting additional roles of histone methylation that may be independent of
traditional effects on specific protein-coding genes.
7. Noncoding RNAs
Before the 1990s, noncoding RNA was often referred to as “junk DNA” that was thought to
have little relevance to biological function. A growing body of research over the past 25 years
has shown that noncoding RNAs have pivotal roles in almost every cellular process investi‐
gated. One class of noncoding RNAs that has received much attention is microRNAs (miR‐
NAs). miRNAs are small transcripts (~22 nucleotides) that regulate gene expression post-
transcriptionally. They are transcribed from DNA in a manner similar to protein-coding
transcripts, where transcription factors recognize promoter sequences upstream of miRNA
genes and initiate transcription (Figure 2). Once transcribed, the several hundred nucleotide
long transcript folds and binds to itself, producing a stem-loop hairpin structure referred to
as a pri-miRNA. The enzyme, Drosha, trims the pri-miRNA into a smaller form known as pre-
miRNA (~70 nucleotides long). Pre-miRNA is then transported out of the nucleus into the
cytoplasm, where the loop portion of the pre-miRNA is cleaved by the enzyme Dicer [39]. Now
as a double-stranded RNA molecule, it is unwound and one strand joins with several proteins
to form the miRNA-induced silencing complex (miRISC). The mature miRNA binds to
complementary sequences in the 3′ untranslated region (UTR) of a target mRNA where
miRISC causes either translational repression, deadenylation, or endonucleolytic cleavage of
the target mRNA, preventing its expression [40]. Importantly, the mature miRNA needs only
~6–8 complementary nucleotides for which to base pair with the 3′ UTR of the target mRNA,
and therefore, one miRNA can target several hundreds of different mRNAs in a given cell. For
this reason, miRNAs have been regarded as “master regulators” of gene expression. Changes
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in miRNA expression can therefore lead to widespread changes in gene expression and
alteration in several cellular signaling cascades. Other types of noncoding RNAs include: (1)
PIWI-interacting RNA (piRNA), which regulates sperm development, (2) small nuclear RNA
(snRNA), which regulates mRNA splicing, and (3) long noncoding RNA (lncRNA), which has
widespread effects on chromatin modification and transcription [41].
Figure 2. MicroRNA processing and function. MicroRNAs are transcribed similarly to protein-coding RNAs, except
they form a stem-loop structure following transcription (i.e., pri-miRNA). The enzyme, Drosha, trims the ends of the
stem (i.e., pre-miRNA) to prepare for exportation from the nucleus via Exportin 5. Once in the cytoplasm, Dicer cleaves
the loop of the pre-miRNA that produces a double-stranded RNA. One strand (i.e., mature miRNA) is chosen to be
incorporated into the miRNA-induced silencing complex (miRISC). Upon binding to a complementary sequence in the
3′ untranslated region of a target mRNA, either translational repression, deadenylation, or endonucleolytic cleavage
may occur. All three mechanisms lead to decreases in protein product.
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8. Noncoding RNA changes associated with drugs of abuse
Given that most drug abuse research has focused on miRNAs, we will focus on this subclass.
One approach to finding candidate addiction-related miRNAs is to examine miRNA expres‐
sion changes within brain regions implicated in addiction following varying levels of drug
exposure. Using this approach, Hollander and colleagues [42] found that rats given extended
(6 h/day), but not restricted (2 h/day), access to cocaine self-administration exhibited upregu‐
lation of miR-212 in the dorsal striatum, a region involved in establishing habitual behavior
[43]. Since the extended access self-administration model produces a behavioral phenotype
that mimics the escalation of drug intake observed in human drug addicts, the findings suggest
that upregulated miR-212 may play a role in the development of compulsive drug taking. One
gene target of miR-212 is MeCP2 [44], a protein whose increased expression in the NAc is
associated with reductions in amphetamine reward CPP [17]. However in the dorsal striatum,
decreases in MeCP2 via miR-212 regulation are associated with decreases in compulsive-like
cocaine self-administration [44]. These findings highlight the importance of examining the
roles of epigenetic modulators across different drug classes, brain regions, and drug abuse
models.
Another approach to identify candidate miRNAs is through bioinformatics. Databases exist
that identify predicted targets of miRNAs and their distribution within the brain. We recently
identified miR-495 as a lead candidate that has targets enriched in the Knowledgebase of
Addiction-Related Genes database [45] and exhibits high expression in the NAc [46]. We found
that cocaine self-administration decreases levels of NAc miR-495 and increases expression of
several addiction-related genes. These effects suggest that cocaine dysregulates NAc miR-495,
leading to disinhibition of addiction-related gene expression.
miRNAs and other noncoding RNAs have also been implicated in brain changes observed
with other drugs of abuse. Alcohol-dependent rats exhibit increases in miR-206 in the medial
PFC (mPFC) [47], a brain region involved in executive control of drug-seeking behavior [48].
miR-206 directly targets and suppresses BDNF expression in the mPFC [47], where increases
in BDNF in this region are associated with inhibiting motivation for cocaine [49, 50]. This
suggests increases in miR-206 likely contribute to the development of alcohol dependency
through suppression of BDNF. Additionally, several lncRNAs exhibit expression changes in
the NAc of heroin addicts postmortem [51]. These promising findings suggest that noncoding
RNAs provide a treasure trove of novel targets for regulating addiction-related gene changes
and behaviors.
9. Pharmacological manipulations of epigenetic mechanisms
Pharmacological agents that target specific epigenetic machinery have been used to further
understand the role of epigenetic mechanisms in the effects of drugs of abuse and to explore
their potential use as treatments for drug addiction. Most preclinical studies have utilized both
Epigenetics and Drug Abuse
http://dx.doi.org/10.5772/101986
29
systemic and intracranial administration of these compounds, where the former has a more
human translational value, while the latter allows for greater brain region specificity.
9.1. Methyl supplementation and DNMT inhibitors.
DNA methylation can be altered pharmacologically by using methionine or DNMT inhibitors.
Methionine is an amino acid commonly found in diet, where methionine metabolism yields
methyl groups that serve as donors for methylating DNA. DNMT inhibitors exert the opposite
effect by preventing DNMT from catalyzing DNA methylation. Daily, systemic administration
of methionine has been shown to reduce both the rewarding and motivating effects of cocaine
in rodents [18, 52]. In contrast, intracranial administration of a DNMT inhibitor (i.e., RG108)
into the NAc increases the rewarding effects of cocaine [18]. However, this same manipulation
decreases drug-seeking behavior following a prolonged abstinence period [53]. These findings
suggest that the effect of DNA methylation in the NAc may depend on whether or not there
has been a period of abstinence following cocaine exposure. Indeed, our lab and others have
shown that dynamic changes occur during forced abstinence from cocaine in animal models,
and that these changes can result in opposing effects of pharmacological challenge on cocaine
abuse-related behavior depending on whether the manipulation occurs during active drug
intake versus abstinence [54–56]. It should be noted that work using DNA methyl supple‐
mentation and DNMT inhibitors has primarily been done with cocaine and needs to be tested
on other drug classes.
9.2. Histone deacetylase inhibitors
The removal of an acetyl group from a histone is catalyzed by histone deacetylases (HDACs).
This reaction results in condensing the chromatin and repressing transcription. HDAC
inhibitors prevent this reaction from occurring, thereby maintaining DNA accessibility. There
are five different classes of HDACs (e.g., I, IIa, IIb, III, and IV) and each class contains multiple
HDAC enzymes (e.g., HDAC1, HDAC8, SIRT1, etc.). HDAC inhibitors range in their selectivity
for specific HDAC classes. Drugs that target both class I and II HDACs (e.g., Tricostatin A,
sodium butyrate, and SAHA) have been found to enhance cocaine locomotor sensitization [21,
57, 58], cocaine and opiate CPP [21, 58, 59], and cocaine self-administration [60] when admin‐
istered systemically prior to cocaine exposure. In contrast, administration of HDAC com‐
pounds following cocaine exposure attenuates cocaine CPP [61]. Similarly, these compounds
appear to produce mixed effects with alcohol, with some reporting increases [62] and others
reporting decreases [63, 64] in consumption. While these effects were found during active drug
administration, HDAC inhibitors have also been shown to alleviate anxiety symptoms during
alcohol withdrawal [30, 65]. Additionally, several studies have found that the effects of the
class I/II HDAC inhibitors were specific to drug self-administration, as no effects were found
with these drugs on food reinforcement [60, 63, 64]. Collectively, it appears that class I/II HDAC
inhibitors can produce both increases and decreases in drug-abuse-related behavior, and that
the effects may vary depending on whether testing occurs during drug exposure or with‐
drawal.
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More consistent effects have been observed with selective HDAC inhibitors. For instance, the
selective class I HDAC inhibitor, MS-275, decreases both alcohol and cocaine abuse-related
behavior in rodents [63, 64, 66, 67]. Also, the highly selective HDAC3 inhibitor, RGF-P966,
decreases cocaine CPP [68]. These findings suggest that the use of more selective HDAC
inhibitors may improve behavioral outcomes.
10. Genetic tools for uncovering epigenetic roles in drug-abuse-related
behavior
While pharmacological approaches have translational value for development of therapeutic
agents, efficacy may be compromised by the widespread drug distribution if the effects of an
epigenetic manipulation vary depending on the brain region of interest. Also, pharmacological
manipulations used to date have widespread effects on the genome, whereas sharpening the
mechanism/location targeted may improve desired outcomes. Recent preclinical research has
shed light on this area with technologies that selectively manipulate genes in specific brain
pathways and cell types.
10.1. Viral vectors
One approach to manipulating a certain gene within a particular brain region is the use of viral
vectors. Viral vectors are constructed to be nonreplicative so that they do not produce more
viral particles after infecting the cell. They enter the cell through endocytosis and insert a gene
of interest (i.e., transgene) into the genome of specific neurons (Figure 3). There are many
different modes of transfection that vary in length from days to months. In order to achieve
high levels of expression in a particular cell type, within the viral vector the transgene is
typically downstream from a promoter sequence that is specific to that cell. Thus, upon viral
transfection, the cells own transcriptional machinery will recognize and bind to the promoter
that will then activate transcription of the transgene. The direction of regulation (i.e., increase
vs. decrease expression) is determined by the sequence of the transgene. For instance, an
increase in gene expression is obtained by inserting the sequence of the transgene into the viral
vector with a strong upstream promoter. In order to decrease gene expression, a couple of
methods may be used. One involves transfecting a short-hairpin RNA (shRNA) that is
processed into a mature short-interfering RNA (siRNA). siRNAs are similar to miRNAs, except
that they are perfectly complementary to the target mRNA and will therefore selectively
downregulate only one target gene, in contrast to the multiple targets of most miRNAs. This
is referred to as a ‘knockdown,’ rather than a ‘knockout,’ as it is preventing translation of the
gene rather than completing deleting it from the genome. In order to accomplish a ‘knockout’
using viral vectors, transgenes that express a new gene editing approach, called the CRISPR-
Cas9 system, can be used. The latter uses a guide RNA that is complementary to specific
sequences in the DNA (e.g., gene of interest) that directs enzymes to that site and excises the
sequence from the DNA, therefore deleting it.
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Figure 3. Viral-mediated gene transfer. Viral particles are infused into a region of interest and infect local cells through
receptor-mediated endocytosis. Once viral particles are released from the vesicle inside the infected cell, viral RNA is
reverse-transcribed into DNA (via reverse transcriptase; dark blue) and transported into the nucleus, where it becomes
integrated into the genome (via integrase; yellow). By using a strong promoter (orange line) upstream of the transgene,
the cell’s transcriptional machinery produces an abundance of viral transgene expression in the cell. TF = transcription
factor.
Research using viral vectors has furthered our understanding of the impact of epigenetic
manipulations on drug-abuse-related behavior. As previously described, DNA methylation is
thought to inhibit cocaine abuse-related behaviors in animal models [16, 18, 52]. To test
whether Dnmt3a expression in the NAc specifically mediates these effects, LaPlant et al. [18]
infused viral vectors into this region that either increased or decreased Dnmt3a levels. Increas‐
ing NAc Dnmt3a expression countered cocaine CPP in mice, while decreasing expression
increased this behavior [18]. Interestingly, this same manipulation also increases depressive-
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like behavior following repeated social stress in mice [18], suggesting the blunted rewarding
effects of cocaine may be due to increases in anhedonia. This illustrates the importance of
testing the role of epigenetic modulators in both drug abuse and mood disorder models.
Another exciting use of viral vectors is to express synthetically engineered transcription factors
that bind to specific sequences in the DNA and regulate histone modifications at one specific
gene loci. Heller and colleagues [69] recently used this approach and found that histone
acetylation or methylation near the fosB gene locus increases or decreases cocaine reward CPP,
respectively. Again, this same manipulation produces either anti- or pro-depressive behaviors,
respectively, following repeated social stress [69], further demonstrating the complex role of
these molecules in both reward and emotional regulation processes. Bidirectional manipula‐
tion of cocaine self-administration in rats has also been demonstrated for miR-212 levels in the
dorsal striatum where viral-mediated increases prevent escalation of cocaine self-administra‐
tion, whereas knockdown increases cocaine self-administration [42]. In some cases, decreasing
miRNA levels may be needed to attenuate addiction-related behavior. For instance, viral-
mediated increases in miR-206 expression in the prefrontal cortex create an alcohol-dependent
phenotype in rats [47], and, therefore, it is possible that decreasing miR-206 levels in the PFC
may be protective against alcoholism. These examples suggest that the development of new
therapeutics that target epigenetic mechanisms have potential for treating addiction. Current‐
ly, there are no pharmacological agents for manipulating miRNAs, although development is
in the initial stages for their delivery in drug compounds [70]. A future challenge for this
avenue of research will be to develop methods of site-selective drug delivery.
10.2. Cre-Lox recombination
Another approach to manipulating gene expression is the use of Cre-Lox recombination
(Figure 4). Cre recombinase is an enzyme that identifies sequences in the DNA called LoxP
sites. When Cre recognizes these sites, it catalyzes a reaction that can either excise or invert the
DNA sequence contained between the two sites, depending on which direction the LoxP sites
are oriented. If the two LoxP sites are in the same direction, Cre will excise the DNA, effectively
deleting a gene that is between those two sites. If the LoxP sites are in the opposite direction,
Cre will then invert the two LoxP sites along with inverting the flanked DNA sequence. This
latter effect allows for gene activation, where a previous nonfunctional inverted gene sequence
becomes functional after Cre-Lox mediated-inversion.
Cre-lox recombination is carried out in rodents that are bred to have LoxP sites at specific
locations in the DNA that flank a gene of interest (e.g., Bdnffl/fl). A viral vector expressing Cre
recombinase can then be infused into a specific brain region and Cre-expressing infected cells
will recognize the LoxP sites and either excise or invert the flanked gene. This will result in
region- and temporal-specific manipulation of gene expression. Another approach with even
greater precision involves breeding mice to express Cre in only certain cell types. This is
accomplished by breeding rodents that express Cre downstream from a promoter that is
specific for only one type or subtype of cells. For instance, Cre can be expressed specifically in
catecholamine neurons when used downstream of a promoter for tyrosine hydroxylase (TH).
TH is an enzyme involved in synthesizing catecholamines (e.g., dopamine). Only cells with
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TH will have the transcriptional machinery to recognize the TH promoter and express Cre.
Next, there are two methods for manipulating gene expression in a cell-type-specific manner.
The first is to crossbreed two transgenic mice: the one that expresses Cre only in certain cell
types (e.g., TH+ neurons) and the other that ubiquitously expresses a LoxP-flanked Bdnf gene
(i.e., Bdnffl/fl). The offspring will no longer express Bdnf in TH-expressing cells. A limitation of
this technique is that Cre recombination occurs at conception and the transgene is either
expressed or deleted permanently. Therefore, changes may occur during development to
compensate for the gene modification, making it difficult to know whether subsequent
functional differences are due to the gene modification or the compensatory changes that
ensued thereafter. Another way to overcome this limitation is to inject a viral vector into a
brain region that contains the gene of interest in a plasmid with the gene flanked by inverted
LoxP sites. While the virus will infect all the cells in that region, only the cells that are expressing
Cre recombinase (e.g., TH+) will recognize the LoxP sites. In this case, Cre recombination will
only occur in specific cell types in a particular brain region and, importantly, during a specific
time point during development.
Figure 4. Cre-lox recombination. The top panel illustrates how Cre-lox recombination can result in gene excision,
where Cre recombinase (red) recognizes two loxP sites in the same orientation and joins the two ends of DNA, then
cleaves one end to join the other, resulting in excision of the flanked gene between the two loxP sites. The middle panel
illustrates how Cre recognizes two loxP sites in opposite orientations and inverts the intervening DNA sequence (e.g.,
Gene X). Gene inversion can be used to turn on a gene that is initially inverted and inactive. The bottom panel depicts
how crossbreeding two transgenic mice that express Cre recombinase only in tyrosine hydroxylase-expressing cells
(TH-Cre) with mice that ubiquitously express Bdnf with flanked loxP sites (Bdnffl/fl) results in mice with deficient Bdnf
expression only in TH+ cells.
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Research employing the Cre-Lox recombination approach has shown that the effect of
epigenetic mechanisms can be cell-type specific. For instance, the histone methytransferase
G9a has differential roles in cocaine-related behaviors depending on whether it is expressed
in striatal neurons that contain dopamine D1 (D1R) versus D2 (D2R) receptors. G9a is down‐
regulated by cocaine in both D1R and D2R-containing neurons; however, Cre-mediated
downregulation of G9a selectively in D1R-neurons is associated with decreasing cocaine CPP
and locomotor behavior in mice, while the opposite effects occur with selective down-
regulation in D2R-neurons [36]. These effects were observed using both Cre-Lox recombinase
procedures described above, providing strong evidence for the cell-type-specific role of G9a
in cocaine abuse-related behavior.
11. Transgenerational epigenetic inheritance of addiction-like phenotypes
Perhaps the most intriguing discovery in epigenetics is that epigenetic marks acquired due to
experience can be passed along to future generations. Unfortunately, this may include
epigenetic changes that make one vulnerable to addiction. The phrase “it runs in the family”
is often spoken in social circles regarding the seeming ability of addiction to be inherited. While
much is known about inheritance based on classical Mendelian genetic inheritance, much less
is known about transgenerational epigenetic inheritance.
Several criteria must be met for transgenerational epigenetic inheritance. First, in order to pass
down epigenetic changes across generations, the changes need to be present in the germ cells
(i.e., sperm or egg). In other words, the epigenetic changes must occur in future generations
independent of behavioral and social transfer, relying only on the molecular transmission of
epigenetic information [71]. Second, the behavioral phenotypes need to persist across several
generations, depending on the sex and pregnancy status of the parent exposed to the initial
environmental trigger. In males and nonpregnant females, an environmental trigger that
affects the parent generation (i.e., F0) and their germ cells, will directly impact the next (i.e.,
F1) generation. This is referred to as multi- or inter-generational inheritance [72]. However, if
the behavioral phenotype persists into the third generation (i.e., F2), which had no direct
exposure to the trigger, it can be regarded as transgenerational inheritance. With pregnant
females, not only is the parent and embryo directly affected, but also the germ cells of the
embryo that will develop into the F2 generation. Therefore, the F3 generation must exhibit the
phenotype to be considered transgenerational. Third, epigenetic modifications present in the
parents need to persist into future generations (see Figure 5). Interestingly, most epigenetic
marks (particularly DNA methylation) are erased immediately in the embryo following
fertilization [73]. Very few exceptions are currently known, but some include imprinted genes
(i.e., methylation-induced silencing of genes in one parent’s allele and not in the others), certain
histone and protamine (i.e., histone-like proteins found in sperm) modifications, and reserve
pools of coding and noncoding RNA [72]. Although narrowing the field of investigation, the
complex pattern of changes required for transgenerational epigenetic inheritance still remains
poorly understood [72, 74].
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Figure 5. Epigenetic inheritance. For pregnant F0 females (top left panel), drug exposure directly affects (red-outlined
symbols) both the F0 female and the fetus, including the brain and germ cells of the upcoming F1 generation. Howev‐
er, the F2 generation also receives direct effects of drug exposure from the F0 generation via the germ cells of the F1
generation. For males (top right panel), drug exposure directly affects both the F0 generation and the germ cells that
lead to the F1 generation. Therefore, the F3 and F2 generation of the pregnant female and male, respectively, can re‐
ceive transgenerational epigenetic inheritance from the F0 generation without having been in direct contact with drugs
of abuse (orange-outlined symbols).
11.1. Drug abuse-related traits passed across generations
The idea that addiction-like phenotypes can be passed down across generations based on
experiences of the parents is compelling in terms of uncovering potential biomarkers that could
be used to predict one’s risk of developing drug addiction. Only a few studies have investi‐
gated this possibility in the context of drug abuse models. Vassoler and colleagues [75] found
that male adult rats with a history of cocaine self-administration passed an addiction-resist‐
ant phenotype onto male, but not female, offspring. One potential mediator of these effects is
mPFC BDNF expression, where both the male F0 generation’s sperm and the mPFC of the
male, but not female, offspring exhibited increased H3 acetylation at the BDNF promoter, as
well as increased BDNF expression in the mPFC of the male offspring. Consistent with this
idea, mPFC BDNF is associated with resilience to drug effects [47, 49, 50]. These data are
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particularly compelling given that it was the father who received the initial trigger (i.e., drug
exposure), thereby avoiding potential confounds of maternal care, social/behavioral transfer,
and in utero environment changes that may occur following drug exposure in the females.
Nonetheless, one cannot rule out potential stress effects during copulation. Gapp et al. [76]
avoided this potential confound by isolating the sperm of the affected F0 males and artificially
inseminating the F0 females. They found that sperm noncoding RNAs from fathers subjected
to early life stress sufficiently passed on molecular and behavioral phenotypes to the next two
generations. Interestingly, early life stress is also a strong predictor for developing drug
addiction [1]. Other studies have shown that repeated morphine administration in F0 female
adolescents produces male offspring that are more sensitive to the analgesic and tolerance
effects of morphine [77]. Furthermore, ethanol exposure to F0 males decreases ethanol intake
and increases sensitivity to the inhibitory effect of ethanol on anxiety-like behavior in F1
offspring [78]. Reduced methylation at the Bdnf promoter was also observed in this study in
both the F0 male sperm and in the F1 males’ VTA. The VTA sends dopaminergic projections
to the NAc and BDNF in the VTA has a facilitating effect on drug-abuse-related behavior [79].
These few examples provide some evidence of multi-generational inheritance of drug abuse-
related traits and associated changes to the epigenome. However, further research is required
to examine if these traits persist into additional generations and whether blocking or reversing
the epigenetic changes in the germline will prevent transmission of these traits. The latter effect
would have very exciting implications for approaches to prevent the development of addiction
in future generations.
12. Concluding remarks
The studies reviewed provide compelling evidence for a link between drug-induced epigenetic
regulation of gene expression and drug abuse-related behavior in animals. The epigenetic
changes in gene expression occur in brain regions involved in reward learning and motivation.
This leads to plasticity-related changes within the neurocircuitries that mediate these processes
and is associated with aberrant behaviors that resemble hallmark symptoms of human drug
addiction, such as escalation of drug intake [42, 44, 80, 81] and increased willingness to exert
effort to obtain drug [46, 82]. Given that epigenetic mechanisms can produce long-lasting
changes in gene expression, they are likely candidate explanations for the persistent nature of
drug addiction in humans.
Current understanding of experience-dependent epigenetic changes is in its infancy. One
notable limitation in this field is the dearth of research on drugs of abuse other than psychos‐
timulants and alcohol. This is a particularly important gap to fill given that regulatory changes
in addiction-related genes can have opposite effects on abuse-related behaviors depending on
drug class [25, 83, 84]. The field also faces many challenges in discerning the involvement of
epigenetic mechanisms in drug addiction given the vast number of molecular regulatory
events that are altered by stress and drug experience, the complex interactions that can occur
among these regulatory events, and their drug-, region-, and time-specificity. Indeed, high
comorbidity exists between drug addiction and stress-related emotional disorders (e.g., PTSD
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and depression) [85, 86]; therefore, additional work is needed to test whether epigenetic factors
underlie the co-occurrence or are specific for one disorder over the other. It will be vital to test
the generalizability versus specificity of epigenetic modifications in drug abuse-related
behavior.
Despite the challenges that lie ahead, growing knowledge in this field will provide opportu‐
nities for novel preventions and interventions of drug abuse and dependence. New technol‐
ogies for identifying and specifically targeting epigenetic processes hold promise not only for
understanding the complex interactions between drug exposure, life experiences, and gene
expression, but also as treatment strategies designed to counter epigenetic dysregulation. For
instance, the use of synthetic transcription factors may allow drug-induced or inherited
epigenetic marks to be erased in order to increase resilience when one is exposed to addictive
drugs [69]. Future epigenetics research may also identify biomarkers of vulnerability that may
aid prevention strategies. Collectively, these new avenues of drug abuse research are exciting
given the urgent need for better treatments of this devastating disorder.
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